Fetal Exposure to GLP-1 Agonists and Oral Hypoglycemic Agents

ESPE Yearbook of Paediatric Endocrinology

ISSN 1662-4009 (online)

An indispensable reference tool endorsed by the European Society for Paediatric Endocrinology

Previous issue | Volume 22 | ESPEYB25

Yearbook of Paediatric Endocrinology 2025

2. Antenatal and Neonatal Endocrinology

Previous section
Hyperinsulinemic Hypoglycemia, Neonatal Diabetes

Table of contents

Next section
PCOS and Birth Outcome

ey0022.2-14 | Fetal Exposure to GLP-1 Agonists and Oral Hypoglycemic Agents

2.14. Maternal GLP-1 receptor activation inhibits fetal growth

ey0022.2-15 | Fetal Exposure to GLP-1 Agonists and Oral Hypoglycemic Agents

2.15. Oral glucose-lowering agents vs insulin for gestational diabetes: a randomized clinical trial

ey0022.2-16 | Fetal Exposure to GLP-1 Agonists and Oral Hypoglycemic Agents

2.16. Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: a population-based cohort study

ESPE Yearbook of Paediatric Endocrinology
ISSN 1662-4009 (Online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more